Stem Cell Investment Archives
Geron Corp Announces Fourth Quarter and Annual 2005
I guess its time to get back into the investment side of things again. I know .. sometimes is not that interesting, but for those of us that watch both sides of the fence of stem cell research .. (that being the science and the stocks) .. we all can likely recognize from investment comes discoveries.
Geron is one of the big boys in stem cell research and stem cell therapy development. So ...
Geron is reporting a net loss for the fourth quarter of 2005 was $8.9 million or $(0.14) per share, compared to $9.5 million or $(0.20) per share for the comparable 2004 period. For fiscal 2005, the company had a net loss of $33.5 million or $(0.58) per share, compared to a net loss of $80.4 million or $(1.79) per share in fiscal 2004.
Not too sexy that .. but more ...
Continue reading "Geron Corp Announces Fourth Quarter and Annual 2005"
Posted on February 28, 2006 03:37 PM | Comments (0)
Cryo-Cell Restructures U-Cord Service to Significantly Enhance Client Value
OLDSMAR, Fla. - CRYO-CELL International, Inc. (OTC BB: CCEL), the world's largest U-Cord stem cell bank, announced today that effective December 6, 2005, the Company has strategically restructured its U-Cord Service to improve clients’ value, increase the Company’s revenues and expand market share.
The restructured U-Cord Service includes several industry-unique features that the Company believes will be viewed very positively by clients when selecting a stem cell bank, by providing families with superior added value and comfort in their relationship with CRYO-CELL as their cord blood stem cell service provider of choice.
...Continue reading "Cryo-Cell Restructures U-Cord Service to Significantly Enhance Client Value"
Posted on January 13, 2006 02:13 PM | Comments (0)
New MultiCell/Thomas Jefferson University Research Collaboration to Evaluate Cell Lines for Hepatitis C Treatment
LINCOLN, R.I., Oct. 20, 2005 – MultiCell Technologies, Inc. (OTCBB: MCET), announced today that the Company has entered into a research collaboration with Thomas Jefferson University, Philadelphia's premier medical and health sciences university, to evaluate the Company's immortalized human hepatocytes as model systems to identify new drugs to treat hepatitis C viral (HCV) infection.
...Posted on October 23, 2005 03:53 PM | Comments (0)
MultiCell Enters into a Joint Venture with Living Cell Technologies
MultiCell Enters into a Joint Venture with Living Cell Technologies to Develop Adult Liver Cell Technologies for Drug Discovery, Protein Production and Therapeutic Clinical Applications
LINCOLN, RI – Tuesday, October 4, 2005 – MultiCell Technologies, Inc. (OTCBB: MCET), a leading adult stem cell company and supplier of immortalized non-tumorigenic human hepatocytes for drug discovery and Living Cell Technologies Limited (LCT), a developer of injectable live cell therapy products to treat life threatening diseases, announced today that the parties have entered into a joint venture to develop therapeutic liver cell applications.
...Continue reading "MultiCell Enters into a Joint Venture with Living Cell Technologies"
Posted on October 23, 2005 03:10 PM | Comments (0)
Chemicon Announces Agreement with Stem Cell Sciences for Exclusive Manufacturing and Marketing of Novel
Chemicon Announces Agreement with Stem Cell Sciences for Exclusive Manufacturing and Marketing of Novel
ATLANTA, GA and EDINBURGH, SCOTLAND – October 6 , 2005 – Serologicals Corporation (NASDAQ: SERO) announced today that Chemicon International, Inc., its wholly-owned subsidiary, and Stem Cell Sciences Holdings LTD (LSE:STEM), have signed an exclusive agreement to manufacture and market novel patent-protected embryonic stem (ES) cell media for the research market.
Under the terms of this agreement, SCS will transfer the patented technology and expertise to Chemicon to allow it to manufacture a fully formulated cell culture media that Chemicon will exclusively market worldwide.
...Posted on October 21, 2005 01:50 PM | Comments (0)
Serologicals Corporation Schedules Third Quarter Earnings Release And Conference Call
ATLANTA, GA – October 17, 2005 – Serologicals Corporation (NASDAQ: SERO) announced today that it will release its third quarter earnings on Thursday, October 27, 2005 after the close of regular trading hours, and then host a conference call on Friday, October 28, 2005 at 11:00 a.m. (ET) to review the results.
The conference call dial-in number is 888-396-2384, International dial-in 617-847-8711, confirmation code 13958054.
...Posted on October 21, 2005 01:41 PM | Comments (0)
Chemicon International Announces Agreement with Axordia for Exclusive Co-Development of Human Embryonic Stem Cell Antibody Markers
ATLANTA, GA and SHEFFIELD, UK – September 30, 2005 – Serologicals Corporation (NASDAQ: SERO) announced today that Chemicon International, Inc., its wholly-owned subsidiary, and Axordia Ltd. have signed an exclusive agreement to co-develop new antibody markers from Axordia's proprietary human embryonic stem (ES) cell lines.
Under the terms of this agreement, Axordia will contribute proprietary expertise and materials for antibody generation and antibody characterization and Chemicon will commercialize the new antibody research tools arising from this collaboration.
...Posted on October 17, 2005 06:17 PM | Comments (0)
Alan L. Rubino Elected To Aastrom Biosciences' Board Of Directors
Ann Arbor, Michigan, September 30, 2005 - Aastrom Biosciences, Inc. (Nasdaq: ASTM) announced today that Alan L. Rubino, a Principal with Watchung Partners, has been elected to the Company's Board of Directors. He will serve as a Class III Director whose term expires at Aastrom's Annual Meeting of Shareholders in 2006. Mr. Rubino has been appointed to the Board's Audit Committee.
"We are excited to welcome Alan Rubino to our Board, as he will be an important industry resource for our Company," said R. Douglas Armstrong, Ph.D., Chief Executive Officer and Chairman of Aastrom.
...Continue reading "Alan L. Rubino Elected To Aastrom Biosciences' Board Of Directors"
Posted on October 17, 2005 06:06 PM | Comments (0)
Stem Cell Therapeutics Corp. and Medicon A/S Announce the Submission of Proposed NTx(TM)-265 European Phase I Clinical Trial Study to the Danish Regulatory Agency
CALGARY, Oct. 3 /CNW/ - Stem Cell Therapeutics Corp. ("SCT") announced today that Medicon A/S ("Medicon") of Birkerod, Denmark has submitted a Phase 1 clinical trial study protocol to the Danish Regulatory Agency on behalf of SCT for its NTx(TM)-265 program for the treatment of stroke. Stroke, the third leading cause of death in the United States and second worldwide, has an incidence of 700,000 patients in the U.S. each year.
With currently available therapies, less than 4% of stroke patients are treated with interventional drugs. The American Heart Association estimated the economic costs in the US at $54B in 2004.
...Posted on October 17, 2005 05:58 PM | Comments (0)
StemCells, Inc. Moves to NASDAQ National Market
PALO ALTO, Calif., (September 30, 2005) – StemCells, Inc. (NASDAQ: STEM) today announced that the Nasdaq Stock Market has approved its application to transfer the listing of its common stock to the National Market from the Capital Market.
...Continue reading "StemCells, Inc. Moves to NASDAQ National Market"
Posted on October 17, 2005 05:55 PM | Comments (0)
Stem Cell Therapeutics Corp. and Medicon A/S Sign Contract to Perform Phase I Clinical Study
CALGARY, Sept. 29 /CNW/ - Stem Cell Therapeutics Corp. ("SCT") announced today that they have signed a contract with Medicon A/S ("Medicon") of Birkerod, Denmark to perform a Phase I clinical trial.
The contract encompasses submission of SCT's Phase I clinical trial protocol, screening, conduct and reporting of trial results. This agreement follows the successful clinical trial feasibility assessment and positive regulatory response that Medicon and SCT have achieved to date.
...Posted on October 17, 2005 05:32 PM | Comments (0)
Stem Cell Therapy International, Inc. Announces Symbol Change to "SCII"
TAMPA, FL, Oct 14, 2005 - Stem Cell Therapy International, Inc. (Other OTC:ATYD.PK), a pioneer in the field of research and development of stem cell transplantation (SCT) therapy and regenerative medicine, announced today that it has changed its stock symbol to OTCBB: SCII.OB and will begin trading under the new stock symbol effective immediately.
...Continue reading "Stem Cell Therapy International, Inc. Announces Symbol Change to "SCII""
Posted on October 17, 2005 05:09 PM | Comments (0)
New Life Scientific, Inc. and UTEK Corporation Announce Strategic Alliance Agreement
FREEHOLD, N.J. and PLANT CITY, Fla. - Sept. 22, 2005 - New Life Scientific, Inc. (OTCBB:NWLF), a company engaged in developing stem cell banks and stem cell treatment facilities, and UTEK Corporation (AMEX:UTK) (LSE-AIM:UTKA), an innovative technology transfer company, announced today the signing of a strategic alliance agreement.
Henry Val, President and Chief Executive Officer of New Life Scientific, Inc., said, "We are enthusiastic about forming a strategic alliance with UTEK Corporation which we believe will enable us to identify synergistic technology acquisition opportunities related to stem cell research."
...Posted on October 4, 2005 05:58 PM | Comments (0)
U.S. BioDefense Receives First Stem Cell Line and Extends Agreement With University of British Columbia
CITY OF INDUSTRY, Calif., Sept. - U.S. BioDefense (OTC BB: UBDE) is pleased to announce today that it has received its first stem cell line as a part of an agreement with the University of British Columbia.
The company will begin evaluation of the neural crest stem cell line before beginning production of a commercial line which will be available for research use by Universities and other biotech companies.
...Posted on October 4, 2005 05:09 PM | Comments (0)
Stem Cell Therapy International Signs Exclusive License Agreement for the Supply of Stem Cells and Use of 26 Related Patents from the Institute of Cell Therapy In Kiev, Ukraine
TAMPA, Fla. - Sept. 19, 2005 - Stem Cell Therapy International, Inc. (OTC: ATYD) today announced that it has signed an exclusive global Licensing Agreement with the Institute of Cell Therapy (ICT) a biotechnology company incorporated and organized in Kiev, Ukraine, for the supply of stem cells and use of 26 related patents.
The agreement is in effect for a period of ten (10) years with an option to renew for another ten (10) and covers access to a worldwide territory for Stem Cell Therapy International, except for five countries, yet to be named.
...Posted on October 4, 2005 04:44 PM | Comments (0)
Stem Cell Therapy International Names Four Leading Scientists to Scientific Advisory Board
Advisory Board to Dramatically Expand Stem Cell Therapy International's Role in the Advancement and Application of Stem Cell Transplantation Therapy
TAMPA, Fla. - Sept. 28, 2005 - Stem Cell Therapy International (OTC:ATYD) today announced the appointment of four leading international scientists in the field of stem cell transplantation therapy to the company's working Scientific Advisory Board.
...Posted on October 3, 2005 04:48 PM | Comments (0)
Viacell to Present at UBS Healthcare Conference
Cambridge, MA, September 21, 2005 ― ViaCell, Inc. (Nasdaq: VIAC) today announced that the company will present at the UBS Global Life Sciences Conference taking place September 26 - 29, 2005 at the Grand Hyatt New York in New York City.
Marc D. Beer, President and Chief Executive Officer, will present an overview of ViaCell’s business activities and product pipeline at 11:00 a.m. on Monday, September 26, 2005.
...Continue reading "Viacell to Present at UBS Healthcare Conference"
Posted on September 27, 2005 05:59 PM | Comments (0)
ThermoGenesis to Present at the UBS Global Life Science Conference
RANCHO CORDOVA, Calif., Sept. 22 - ThermoGenesis Corp. (Nasdaq: KOOL) announced today that Philip Coelho, Chairman and Chief Executive Officer, will participate in the UBS Global Life Science Conference on Wednesday, September 28, 2005 at 3:00 pm EDT.
Mr. Coelho will present an overview of the company's business activities and product pipeline. The UBS Conference will be held at the Grand Hyatt Hotel in New York, NY.
Continue reading "ThermoGenesis to Present at the UBS Global Life Science Conference"
Posted on September 27, 2005 05:46 PM | Comments (0)
Viacell Suspends Enrollment in CB001 Phase I Clinical Trial
Cambridge, MA, September 19, 2005 - ViaCell, Inc. (NASDAQ: VIAC) today announced that it has suspended enrollment in its Phase I clinical trial of CB001, an investigational cord blood stem cell product for hematopoietic stem cell transplantation being studied for the treatment of a variety of cancers.
Of the eight patients who have completed treatment in the study, two experienced Grade IV acute graft-versus-host-disease, or aGVHD, a known potential side effect in transplantation. Both patients have recovered from the aGVHD, however, under the study protocol, the occurrence of two cases calls for a suspension of enrollment in the trial.
...Continue reading "Viacell Suspends Enrollment in CB001 Phase I Clinical Trial"
Posted on September 27, 2005 05:37 PM | Comments (0)
Geron Corporation Announces Exercise Of Over-Allotment Option
Menlo Park, CA – September 20, 2005 – Geron Corporation (Nasdaq: GERN) today announced that on Monday, September 19, 2005, the underwriters of its public offering of six million shares of common stock have exercised their over-allotment option in full to purchase 900,000 additional shares, resulting in an additional gross public offering price of $8.1 million.
The public offering and over-allotment exercise are expected to close on September 21, 2005.
...Continue reading "Geron Corporation Announces Exercise Of Over-Allotment Option"
Posted on September 22, 2005 06:08 PM | Comments (0)
Additional Stem Cell Articles In This Category
* MultiCell Technologies Awarded Pilot Grant for Study of Type 1 Di* Progenitor Cell Therapy Inks Manufacturing Deal with Cellerant Th
* MultiCell Forms New Company to Develop Novel Therapies for Diabet
* Geron Corporation Announces The Pricing Of Its Common Stock Offer
* U.S. BioDefense Receives Positive Industry Response to Neural Ste
* Cord Blood America Secures $5 Million Financing Agreement
* Geron Corporation Announces Common Stock Offering
* Cytori Therapeutics Demonstrates Adipose-Derived Adult Stem and R
* Published Study Shows First Direct Link Between Human Neural Stem
* Multicell Held Grand Opening At Rhode Island Facilities; Governor
* PharmaFrontiers to Present at ValueRich Small Cap Financial Expos
* StemCells Appoints Rodney K.B. Young CFO and VP, Finance
* ThermoGenesis Corp. Announces Fourth Quarter and Year End Results
* Geron Announces Publication of Studies Demonstrating Engraftment
* New Life Scientific, Inc. to Present at the ValueRich Small Cap F
* Invitrogen Promotes David Onions, Ph.D. to Chief Medical Officer
* Mesoblast Commences Bone Regeneration Trials At Colorado State Un
* Serologicals Corporation To Present At Thomas Weisel Partners Hea
* ViaCell Announces Publication of Preclinical Study Demonstrating
* MultiCell Receives SBIR Grant for Protein Development for Critica
* U.S. BioDefense Stem Cell Initiative Positively Featured in Calif
* ViaCell Announces Expansion of Amgen Collaboration and License Ag
* Cytori Therapeutics Announces Fall Medical Conference Presentatio
* Singapore Wants Everyone To Know They Do Stem Cell Research Too
* Bio-Matrix Scientific and Cord Blood America Sign Strategic Allia
* Cord Blood America Signs Agreement with NeoStem, Launches Adult S
* Cord Blood America Reports Year to Date Revenues of $1.485M
* Lantos Affirms Support of Expanded Stem Cell Research - Applauds
* Biotech Investment - 2005 IPO's Looking Good
* ViaCell, Inc. Reports Second Quarter 2005 Financial Results
* Favrille Reports Second Quarter 2005 Financial Results
* Johns Hopkins Top Of Research Funding List
* Curis to Release 2005 Second Quarter Financial Results and Hold C
* Tulane Gene Therapy Center Receives $10 Million Grant For Stem Ce
* AnorMED Reports Fiscal 2006 First Quarter Results, Progress on Ph
* New Survey of Drug Industry Professionals Finds Strong Support fo
* Stem Cell Stocks See Gains On News From Frist
* StemCyte, Inc. Completes Significant Round of Financing
* Regal One Distributes American Stem Cell Stock to Its Shareholder
* Chemokine Therapeutics' Cancer Drug Granted Orphan-Drug Designati
* Bioindustry Disappointed by Commission's Uncertain Position on Pa
* Stem Cell Institute Must Abide by 'Good Government' Rules Before
* PhereSys Therapeutics Corp. Sheet
* New Investment Report Reveals Rapid Growth of Stem Cell Technolog
* Adult Stem Cell Research Eases Concerns Regarding Embryonic Stem
* Regaltech Exploring Acquisition Opportunities
* Favrille, Inc. Reports Data From Phase II Clinical Trial
* Favrille, Inc. Announces Status of Patient Enrollment in Phase II
* StemCyte Corp. Sheet
* MultiCell Announces Results of Shareholders' Meeting
* Mount Sinai School of Medicine establishes stem cell institute
* Venture Capital Firms Get Ready For Stem Cell Research In San Fra
* Stem Cell Grants From Harvard
* Curis Reports First Quarter 2005 Results
* Stem Cell Sciences (STEM) Corp. Sheet
* IRRC’s Primer on Stem Cell Research Assists Institutional Inves
* IRRC’s Primer on Stem Cell Research Assists Institutional Inves
* Bio-Matrix Scientific Group Appoints Dr. Geoffrey O'Neill -- Form
* RainMakers International Acquisition Is Expected to Beat Revenue
* Cord Blood Registry Reports Record Growth in Revenue
* Cord Blood Company Viacell 2004 Financials
* On the Eve of Viacell's Financials, CBR Sues Viacell
* Stem-Cell Firms Rise On Funding News
* Cord Blood Researcher Viacell To Release First Financials Since I
* US Patent Office Rejects PharmaStem Cord Blood Stem Cell Patents
* BrainStorm Cell Therapeutics Raises $1.5m Seed Funding
* Cord Blood America Announces Acquisition of RainMakers Internatio
* ThromboGenics Ltd. Corp. Sheet
* CHEMICON International Corp. Sheet
* MultiCell Technologies Completes $4 Million Private Placement
* BrainStorm Cell Therapeutics Launches into Next Phase with the Le
* Curis Reports Fourth Quarter and Year-End 2004 Financial Results
* PharmaFrontiers Makes Key Research Advances in Multiple Sclerosis
* Bio-Matrix Files Provisional Patent with U.S. Patent Office
* California: San Mateo Wants to Be Home to Stem-Cell Group
* Aastrom Biosciences Announces FDA Approval for Expanded Clinical
* Genzyme Swings To 4Q Loss On Acquisition Charges
* Stock Report for Week Ending Feb 11 ... Mixed Bag
* California: U.S. BioDefense Plans Response for Funding and Buildi
* CRYO-CELL International, Inc. Announced Increased Revenues Fiscal
* Genzyme Acquires Verigen AG
* AnorMED Announces Fiscal 2005 Third Quarter Results and Upcoming
* Stock Report for Feb 1 ... Curis and Aastrom Gains
* UBDF 3:1 Forward Split Effective Monday
* Stem Cell Stocks Up Last Friday
* Stem Cell Stocks Take a Beating
* Stem-cell Stocks Damaged by Study Showing Contamination
* AVI BioPharma gets stem-cell use patent
* More on Stem Cell Companies and Stock Tracking
* Stem Cell Research Company Stock Charts
* Stem Cell Therapeutics Corp. to Begin Public Trading Today
* An Investors Perspective on Stem Cell Research Companies